Neurocrine Biosciences, Inc.
NBIX
$155.80
$5.213.46%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.10B | 2.86B | 2.68B | 2.51B | 2.41B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.10B | 2.86B | 2.68B | 2.51B | 2.41B |
| Cost of Revenue | 1.11B | 1.07B | 986.90M | 925.90M | 870.60M |
| Gross Profit | 2.00B | 1.79B | 1.70B | 1.58B | 1.54B |
| SG&A Expenses | 1.20B | 1.16B | 1.14B | 1.08B | 1.03B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.30B | 2.22B | 2.13B | 2.01B | 1.90B |
| Operating Income | 798.10M | 635.80M | 553.60M | 499.10M | 515.40M |
| Income Before Tax | 937.50M | 705.40M | 628.60M | 527.10M | 466.20M |
| Income Tax Expenses | 268.90M | 226.80M | 200.60M | 178.80M | 160.40M |
| Earnings from Continuing Operations | 668.60 | 478.60 | 428.00 | 348.30 | 305.80 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 668.60M | 478.60M | 428.00M | 348.30M | 305.80M |
| EBIT | 798.10M | 635.80M | 553.60M | 499.10M | 515.40M |
| EBITDA | 827.90M | 665.90M | 583.30M | 527.60M | 543.90M |
| EPS Basic | 6.70 | 4.81 | 4.30 | 3.48 | 3.04 |
| Normalized Basic EPS | 5.61 | 4.56 | 4.02 | 3.67 | 3.76 |
| EPS Diluted | 6.49 | 4.66 | 4.18 | 3.38 | 2.95 |
| Normalized Diluted EPS | 5.44 | 4.42 | 3.92 | 3.57 | 3.65 |
| Average Basic Shares Outstanding | 398.80M | 398.00M | 398.10M | 399.80M | 401.60M |
| Average Diluted Shares Outstanding | 410.60M | 409.70M | 408.90M | 410.70M | 413.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |